Fresenius Signs Biosimilar Deal With WuXi Biologics
The agreement gives Fresenius exclusive access to up to 37 biosimilar candidates over the next decade, as the company signals a significant expansion of its Biopharma ambitions.
Updated on Nov. 2, 2026 in Biotech
Fresenius signed a biosimilar development agreement with WuXi Biologics, a China-based company, on Monday, November 2, 2026. The deal gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade.
Why it matters
The identified candidates address more than €370 billion ($414 billion) in originator sales and could expand Fresenius' molecules from 29 to as many as 66 by the next decade. The move signals a significant expansion of the company's long-term Biopharma ambitions.
The portfolio spans 13 therapeutic areas and includes monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Development timelines and regulatory milestones for the candidates were not detailed in the announcement.
The players
Fresenius
Fresenius is a German healthcare company with operations spanning clinical nutrition, dialysis and biopharmaceuticals.
WuXi Biologics
WuXi Biologics is a China-based contract development and manufacturing company specializing in biologic drugs.
The details
Biosimilar drugs are drugs that are very close to already approved drugs. Under the agreement, Fresenius and WuXi Biologics will develop candidates across monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Fresenius also confirmed financial targets for 2026 and the medium term.
Timeline
Monday, November 2, 2026: Fresenius announces the WuXi Biologics agreement.
2026: Fresenius financial targets confirmed for the year.
Over the next decade: Exclusive access to up to 37 biosimilar candidates.
The Tech Race
The agreement extends a broader pattern of biosimilar pipeline partnerships built around monoclonal antibodies, a drug class whose patent expirations have opened large originator markets to lower-cost alternatives. It positions Fresenius to compete for a share of the more than €370 billion in originator sales the candidates address.
For patients and payers, biosimilars are typically designed to offer lower-cost alternatives to established biologic treatments. The timing of any resulting products reaching pharmacies or hospitals was not specified in the announcement.
The takeaway
The agreement shows how biosimilar partnerships are being scaled into long-term pipelines rather than single-product deals. Readers tracking drug costs should watch for development milestones and regulatory filings tied to the 37 candidates.
Further reading
For more on the science behind these copies of approved drugs, explore Biotech coverage.
